{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:56:52Z","timestamp":1792663012404,"version":"4.5.0"},"reference-count":91,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1562,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1365-2796.2011.02376.x","type":"journal-article","created":{"date-parts":[[2011,3,14]],"date-time":"2011-03-14T15:58:51Z","timestamp":1300118331000},"page":"604-613","source":"Crossref","is-referenced-by-count":95,"title":["Novel therapies for coeliac disease"],"prefix":"10.1111","volume":"269","author":[{"given":"L. M.","family":"Sollid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,5,23]]},"reference":[{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMra071600","article-title":"Coeliac disease","volume":"357","author":"Green","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nri885","article-title":"Coeliac disease: dissecting a complex inflammatory disorder","volume":"2","author":"Sollid","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nm0797-797","article-title":"Identification of tissue transglutaminase as the autoantigen of coeliac disease","volume":"3","author":"Dieterich","year":"1997","journal-title":"Nat Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0016-5085(98)70007-1","article-title":"Autoantibodies to tissue transglutaminase as predictors of coeliac disease","volume":"115","author":"Dieterich","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0016-5085(98)70008-3","article-title":"Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting coeliac disease","volume":"115","author":"Sulkanen","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ncpgasthep0111","article-title":"Future therapeutic options for coeliac disease","volume":"2","author":"Sollid","year":"2005","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1445-5994.2008.01741.x","article-title":"Coeliac disease: current approach and future prospects","volume":"38","author":"Anderson","year":"2008","journal-title":"Intern Med J"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2009.05.002","article-title":"New therapeutic strategies for coeliac disease","volume":"9","author":"Lerner","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1053\/j.gastro.2009.09.008","article-title":"Coeliac disease: from pathogenesis to novel therapies","volume":"137","author":"Schuppan","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/ng2058","article-title":"A genome-wide association study for coeliac disease identifies risk variants in the region harboring IL2 and IL21","volume":"39","author":"van Heel","year":"2007","journal-title":"Nat Genet"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/gut.37.6.766","article-title":"Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma","volume":"37","author":"Nilsen","year":"1995","journal-title":"Gut"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ng.543","article-title":"Multiple common variants for coeliac disease influencing immune gene expression","volume":"42","author":"Dubois","year":"2010","journal-title":"Nat Genet"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.molmed.2010.09.003","article-title":"A genetic perspective on coeliac disease","volume":"16","author":"Trynka","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1126\/science.1074129","article-title":"Structural basis for gluten intolerance in coeliac sprue","volume":"297","author":"Shan","year":"2002","journal-title":"Science"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nm0698-713","article-title":"Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells","volume":"4","author":"Molberg","year":"1998","journal-title":"Nat Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4049\/jimmunol.161.4.1585","article-title":"Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity","volume":"161","author":"van de Wal","year":"1998","journal-title":"J Immunol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1073\/pnas.0306885101","article-title":"Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in coeliac disease","volume":"101","author":"Kim","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.immuni.2007.05.015","article-title":"A structural and immunological basis for the role of human leukocyte antigen DQ8 in coeliac disease","volume":"27","author":"Henderson","year":"2007","journal-title":"Immunity"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(00)02169-3","article-title":"Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease","volume":"355","author":"Fasano","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2004.06.018","article-title":"A direct role for NKG2D\/MICA interaction in villous atrophy during coeliac disease","volume":"21","author":"H\u00fce","year":"2004","journal-title":"Immunity"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.immuni.2004.06.020","article-title":"Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in coeliac disease","volume":"21","author":"Meresse","year":"2004","journal-title":"Immunity"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nri2670","article-title":"Tissue-mediated control of immunopathology in coeliac disease","volume":"9","author":"Jabri","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000092639","article-title":"Therapy with budesonide in patients with refractory sprue","volume":"73","author":"Daum","year":"2006","journal-title":"Digestion"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1111\/j.1572-0241.2007.01380.x","article-title":"Budesonide in the treatment of refractory coeliac disease","volume":"102","author":"Brar","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1440-1681.2009.05211.x","article-title":"Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: an in vivo\/in vitro pilot study","volume":"36","author":"Ciacci","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1365-2036.2006.03155.x","article-title":"Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis","volume":"24","author":"Rautiainen","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"G996","DOI":"10.1152\/ajpgi.00136.2002","article-title":"Intestinal digestive resistance of immunodominant gliadin peptides","volume":"283","author":"Hausch","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.104.068429","article-title":"Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo","volume":"311","author":"Piper","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1124\/jpet.104.073312","article-title":"Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization","volume":"312","author":"Marti","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1542-3565(05)00366-6","article-title":"Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in coeliac sprue","volume":"3","author":"Pyle","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chembiol.2006.04.008","article-title":"Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease","volume":"13","author":"Bethune","year":"2006","journal-title":"Chem Biol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.chembiol.2006.04.009","article-title":"Rational design of combination enzyme therapy for coeliac sprue","volume":"13","author":"Siegel","year":"2006","journal-title":"Chem Biol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/jpet.106.104315","article-title":"Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat","volume":"318","author":"Gass","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"G621","DOI":"10.1152\/ajpgi.00034.2006","article-title":"Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for coeliac disease","volume":"291","author":"Stepniak","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.gastro.2007.04.008","article-title":"Enhancement of dietary protein digestion by conjugated bile acids","volume":"133","author":"Gass","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gut.2006.111609","article-title":"Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease","volume":"57","author":"Mitea","year":"2008","journal-title":"Gut"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clim.2009.11.001","article-title":"The effects of ALV003 pre-digestion of gluten on immune response and symptoms in coeliac disease in vivo","volume":"134","author":"Tye-Din","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"e6313","DOI":"10.1371\/journal.pone.0006313","article-title":"A food-grade enzyme preparation with modest gluten detoxification properties","volume":"4","author":"Ehren","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/bip.21109","article-title":"Interaction of alpha-gliadin with poly(HEMA-co-SS): structural characterization and biological implication","volume":"91","author":"Liang","year":"2009","journal-title":"Biopolymers"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/bip.21352","article-title":"Interaction of alpha-gliadin with polyanions: design considerations for sequestrants used in supportive treatment of coeliac disease","volume":"93","author":"Liang","year":"2010","journal-title":"Biopolymers"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.gastro.2008.09.016","article-title":"Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium","volume":"136","author":"Pinier","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/00365520500235334","article-title":"Gliadin, zonulin and gut permeability: effects on coeliac and non-coeliac intestinal mucosa and intestinal cell lines","volume":"41","author":"Drago","year":"2006","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10620-009-0813-5","article-title":"A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in coeliac disease patients on a gluten-free diet","volume":"55","author":"Duerksen","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1542-3565(04)00778-5","article-title":"Permeability, zonulin production, and enteropathy in dermatitis herpetiformis","volume":"3","author":"Smecuol","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"16799","DOI":"10.1073\/pnas.0906773106","article-title":"Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2","volume":"106","author":"Tripathi","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1242\/jcs.113.24.4435","article-title":"Human zonulin, a potential modulator of intestinal tight junctions","volume":"24","author":"Wang","year":"2000","journal-title":"J Cell Sci"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2036.2007.03413.x","article-title":"The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study","volume":"26","author":"Paterson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"20673","DOI":"10.1074\/jbc.M010846200","article-title":"Targeted inactivation of Gh\/tissue transglutaminase II","volume":"276","author":"Nanda","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/MCB.21.1.148-155.2001","article-title":"Gene disruption of tissue transglutaminase","volume":"21","author":"De Laurenzi","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1016\/S0968-0896(01)00228-0","article-title":"Synthesis and evaluation of novel dipeptide-bound 1,2,4-thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase","volume":"9","author":"Marrano","year":"2001","journal-title":"Bioorg Med Chem"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0968-0896(01)00292-9","article-title":"Synthesis of dipeptide-bound epoxides and alpha,beta-unsaturated amides as potential irreversible transglutaminase inhibitors","volume":"10","author":"de Macedo","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.chembiol.2005.02.007","article-title":"Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2","volume":"12","author":"Choi","year":"2005","journal-title":"Chem Biol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.1021\/jm060839a","article-title":"Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles","volume":"49","author":"Watts","year":"2006","journal-title":"J Med Chem"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.bmcl.2005.02.005","article-title":"Structure-activity relationship study of novel tissue transglutaminase inhibitors","volume":"15","author":"Duval","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1021\/jo8004843","article-title":"Cinnamoyl inhibitors of tissue transglutaminase","volume":"73","author":"Pardin","year":"2008","journal-title":"J Org Chem"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bmcl.2009.12.011","article-title":"Potent transglutaminase inhibitors, aryl beta-aminoethyl ketones","volume":"20","author":"Ozaki","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB57|cit57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2010.12.037","article-title":"Acylidene oxoindoles: a new class of reversible inhibitors of human transglutaminase 2","author":"Kl\u00f6ck","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"e1861","DOI":"10.1371\/journal.pone.0001861","article-title":"Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury","volume":"3","author":"Siegel","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2741\/2111","article-title":"Transglutaminase 2 in neurodegenerative disorders","volume":"12","author":"Ruan","year":"2007","journal-title":"Front Biosci"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2353\/ajpath.2008.080025","article-title":"Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration","volume":"173","author":"Shweke","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1158\/0008-5472.CAN-09-1257","article-title":"Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase","volume":"69","author":"Shao","year":"2009","journal-title":"Cancer Res"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1016\/j.bmc.2007.07.001","article-title":"Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in coeliac disease","volume":"15","author":"Xia","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.bmc.2007.10.091","article-title":"Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with coeliac disease","volume":"16","author":"Kapoerchan","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.molimm.2009.10.036","article-title":"Design, synthesis and evaluation of high-affinity binders for the coeliac disease associated HLA-DQ2 molecule","volume":"47","author":"Kapoerchan","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.humimm.2010.01.021","article-title":"Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library","volume":"71","author":"J\u00fcse","year":"2010","journal-title":"Hum Immunol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1038\/nm1226","article-title":"Peptide-based therapeutic vaccines for allergic and autoimmune diseases","volume":"11","author":"Larche","year":"2005","journal-title":"Nat Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(02)09332-7","article-title":"Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial","volume":"360","author":"Oldfield","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1371\/journal.pmed.0020078","article-title":"T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity","volume":"2","author":"Verhoef","year":"2005","journal-title":"PLoS Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1084\/jem.191.4.603","article-title":"The intestinal T cell response to \u03b1-gliadin in adult coeliac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase","volume":"191","author":"Arentz-Hansen","year":"2000","journal-title":"J Exp Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"41ra51","DOI":"10.1126\/scitranslmed.3001012","article-title":"Comprehensive, quantitative mapping of T cell epitopes in gluten in coeliac disease","volume":"2","author":"Tye-Din","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1172\/JCI27620","article-title":"HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in coeliac disease","volume":"116","author":"Tollefsen","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.4049\/jimmunol.0802891","article-title":"Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo DQ8 transgenic mice","volume":"183","author":"Huibregtse","year":"2009","journal-title":"J Immunol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/jir.2008.0057","article-title":"Interferon-gamma regulation of intestinal epithelial permeability","volume":"29","author":"Beaurepaire","year":"2009","journal-title":"J Interferon Cytokine Res"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1091\/mbc.E05-03-0193","article-title":"Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane","volume":"16","author":"Utech","year":"2005","journal-title":"Mol Biol Cell"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.proghi.2007.01.001","article-title":"Role of tight junctions in cell proliferation and cancer","volume":"42","author":"Gonzalez-Mariscal","year":"2007","journal-title":"Prog Histochem Cytochem"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/neu.2006.23.309","article-title":"Targeting Rho to stimulate repair after spinal cord injury","volume":"23","author":"McKerracher","year":"2006","journal-title":"J Neurotrauma"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2174\/156802609789044452","article-title":"Rho kinase (ROCK) inhibitors and their application to inflammatory disorders","volume":"9","author":"LoGrasso","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ibd.21038","article-title":"Fontolizumab in moderate to severe Crohn\u2019s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study","volume":"16","author":"Reinisch","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clim.2009.04.007","article-title":"Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5\u2003years","volume":"132","author":"Herold","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/0091270009349376","article-title":"Pharmacokinetics and pharmacodynamics of a chimeric\/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus","volume":"50","author":"Wiczling","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2009.205443","article-title":"Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis","volume":"59","author":"Sandborn","year":"2010","journal-title":"Gut"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrendo.2009.275","article-title":"Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?","volume":"6","author":"Chatenoud","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","article-title":"A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients","volume":"9","author":"Pescovitz","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/gut.41.6.851","article-title":"Autoantibodies in coeliac disease: tissue transglutaminase - guilt by association?","volume":"41","author":"Sollid","year":"1997","journal-title":"Gut"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1182\/blood-2010-01-266536","article-title":"Steady state generation of mucosal IgA+ plasmablasts is not abrogated by B cell depletion therapy with rituximab","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"15849","DOI":"10.1073\/pnas.0908834106","article-title":"Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes","volume":"106","author":"Yokoyama","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1124\/jpet.110.169714","article-title":"Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease","volume":"335","author":"Walters","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/gut.2004.059998","article-title":"T cells in peripheral blood after gluten challenge in coeliac disease","volume":"54","author":"Anderson","year":"2005","journal-title":"Gut"},{"key":"10.1111\/j.1365-2796.2011.02376.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1073\/pnas.0608610104","article-title":"Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of coeliac disease patients","volume":"104","author":"R\u00e1ki","year":"2007","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2796.2011.02376.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2796.2011.02376.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T18:38:32Z","timestamp":1685990312000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2796.2011.02376.x"}},"subtitle":["Symposium: New coeliac disease therapies"],"short-title":[],"issued":{"date-parts":[[2011,5,23]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02376.x","relation":{},"ISSN":["0954-6820"],"issn-type":[{"value":"0954-6820","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,23]]}}}